# Pharmacoinvasive Therapy With Prourokinase

> **NCT01642667** · PHASE2,PHASE3 · COMPLETED · sponsor: **Suzhou Landing Pharmaceuticals** · enrollment: 197 (actual)

## Conditions studied

- ST-segment Elevation Myocardial Infarction (STEMI)

## Interventions

- **DRUG:** Prourokinase
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01642667
- **Lead sponsor:** Suzhou Landing Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-11
- **Final completion:** 2010-12
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2012-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01642667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01642667, "Pharmacoinvasive Therapy With Prourokinase". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01642667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*